From: Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis
 |  | Outcome | ||
---|---|---|---|---|
All patients | Remission | Progression | p | |
N=33 | N=17 (51) * | N=16 (49) | ||
Gender (M/F) N(%) | 18/15 (54/46) | 6/11 | 12/4 | 0.016†|
Age (yrs) | 49±12 (19–79) | 50±9 | 47±15 | n.s. |
Smoking habits (never/ex/current) N(%) | 5/12/16 (15/36/49) | 5/5/7 | 0/7/9 | 0.055†|
BMI (kg/m2) | 26±5 (19–36) | 28±4 | 25±5 | n.s. |
PaO2 (mmHg) | 72±15 (47–117) | 78±13 | 63±12 | 0.002 |
A-aDO2 (mmHg) | 37±14 (11–63) | 31±11 | 44±14 | 0.005 |
VC (% pred) | 80±16 (44–123) | 88±13 | 69±13 | 0.001 |
FEV1 (% pred) | 75±16 (43–104) | 80±15 | 67±13 | 0.014 |
TLC (% pred) | 79±17 (42–116) | 85±16 | 70±14 | 0.009 |
DLCO (% pred) | 57±19 (21–96) | 66±12 | 42±13 | 0.001 |
GM-CSF autoantibody (μg/mL) § | 48±22 | 60±17 | 44±13 | 0.55 |
KL-6 (U/mL) | 2049±1893 | 1084±585 | 3334±2267 | 0.001 |
LDH (IU/L) § | 283±93 (140–522) | 243±69 | 338±103 | 0.005 |
CEA (ng/mL) § | 8.5±7 (1–27) | 6±4.5 | 12±5.5 | 0.048 |